{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:32:32Z","timestamp":1793521952466,"version":"4.5.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"11","funder":[{"name":"German Federal Ministry of Education and Research","award":["031A424"],"award-info":[{"award-number":["031A424"]}]},{"name":"German Federal Ministry of Education and Research","award":["031A315"],"award-info":[{"award-number":["031A315"]}]},{"name":"ERA-Net ERACoSysMed JTC-2 project","award":["031L0136A"],"award-info":[{"award-number":["031L0136A"]}]},{"DOI":"10.13039\/501100002322","name":"CAPES P\u00f3s-Doutorado no Exterior","doi-asserted-by":"publisher","award":["88881.119037\/2016-01"],"award-info":[{"award-number":["88881.119037\/2016-01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Recent clinical findings in patients with chronic myeloid leukemia (CML) suggest that the risk of molecular recurrence after stopping tyrosine kinase inhibitor (TKI) treatment substantially depends on an individual's leukemia-specific immune response. However, it is still not possible to prospectively identify patients that will remain in treatment-free remission (TFR). Here, we used an ordinary differential equation model for CML, which explicitly includes an antileukemic immunologic effect, and applied it to 21 patients with CML for whom BCR-ABL1\/ABL1 time courses had been quantified before and after TKI cessation. Immunologic control was conceptually necessary to explain TFR as observed in about half of the patients. Fitting the model simulations to data, we identified patient-specific parameters and classified patients into three different groups according to their predicted immune system configuration (\u201cimmunologic landscapes\u201d). While one class of patients required complete CML eradication to achieve TFR, other patients were able to control residual leukemia levels after treatment cessation. Among them were a third class of patients that maintained TFR only if an optimal balance between leukemia abundance and immunologic activation was achieved before treatment cessation. Model simulations further suggested that changes in the BCR-ABL1 dynamics resulting from TKI dose reduction convey information about the patient-specific immune system and allow prediction of outcome after treatment cessation. This inference of individual immunologic configurations based on treatment alterations can also be applied to other cancer types in which the endogenous immune system supports maintenance therapy, long-term disease control, or even cure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance:<\/jats:title>\n                  <jats:p>This mathematical modeling approach provides strong evidence that different immunologic configurations in patients with CML determine their response to therapy cessation and that dose reductions can help to prospectively infer different risk groups.<\/jats:p>\n                  <jats:p>See related commentary by Triche Jr, p. 2083<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/0008-5472.can-19-2175","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T19:05:14Z","timestamp":1581361514000},"page":"2394-2406","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML"],"prefix":"10.1158","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4254-2399","authenticated-orcid":false,"given":"Tom","family":"H\u00e4hnel","sequence":"first","affiliation":[{"name":"1Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-1453","authenticated-orcid":false,"given":"Christoph","family":"Baldow","sequence":"additional","affiliation":[{"name":"1Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-487X","authenticated-orcid":false,"given":"Jo\u00eblle","family":"Guilhot","sequence":"additional","affiliation":[{"name":"2INSERM CIC 1402 - CHU Poitiers, Poitiers, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-487X","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[{"name":"2INSERM CIC 1402 - CHU Poitiers, Poitiers, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[{"name":"3III. Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Heidelberg University, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[{"name":"4Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland."},{"name":"5Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Jilg","sequence":"additional","affiliation":[{"name":"6III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp J.","family":"Jost","sequence":"additional","affiliation":[{"name":"6III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2728-7243","authenticated-orcid":false,"given":"Stephanie","family":"Dulucq","sequence":"additional","affiliation":[{"name":"7Laboratory of Hematology, University Hospital of Bordeaux, Bordeaux, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"8Bergonie Institute, INSERM U1218, University of Bordeaux, Bordeaux, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Roeder","sequence":"additional","affiliation":[{"name":"1Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden, Dresden, Germany."},{"name":"9National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur C.","family":"Fassoni","sequence":"additional","affiliation":[{"name":"10Instituto de Matem\u00e1tica e Computa\u00e7\u00e3o, Universidade Federal de Itajub\u00e1, Itajub\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2524-1199","authenticated-orcid":false,"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[{"name":"1Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit\u00e4t Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"2022061706322018300_bib1","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"2022061706322018300_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.01.005","article-title":"Current approach to the treatment of chronic myeloid leukaemia","volume":"55","author":"Pasic","year":"2017","journal-title":"Leuk Res"},{"key":"2022061706322018300_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706322018300_bib4","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet North Am Ed"},{"key":"2022061706322018300_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"2022061706322018300_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"key":"2022061706322018300_bib7","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061706322018300_bib8","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"key":"2022061706322018300_bib9","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","article-title":"Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data","volume":"103","author":"Fassoni","year":"2018","journal-title":"Haematologica"},{"key":"2022061706322018300_bib10","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022061706322018300_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"2022061706322018300_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022061706322018300_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022061706322018300_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022061706322018300_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"2022061706322018300_bib16","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"key":"2022061706322018300_bib17","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"2022061706322018300_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"key":"2022061706322018300_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"2022061706322018300_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Sch\u00fctz","year":"2017","journal-title":"Leukemia"},{"key":"2022061706322018300_bib21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"2022061706322018300_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2022061706322018300_bib23","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrc4029","article-title":"The mathematics of cancer: integrating quantitative models","volume":"15","author":"Altrock","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2022061706322018300_bib24","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1158\/1078-0432.CCR-19-0006","article-title":"Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy","volume":"25","author":"West","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022061706322018300_bib25","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1007\/s11538-019-00640-x","article-title":"Mathematical models of cancer: when to predict novel therapies, and when not to","volume":"81","author":"Brady","year":"2019","journal-title":"Bull Math Biol"},{"key":"2022061706322018300_bib26","doi-asserted-by":"crossref","DOI":"10.1101\/495184","article-title":"The Goldilocks window of personalized chemotherapy: an immune perspective [Internet]","author":"Park","year":"2018"},{"key":"2022061706322018300_bib27","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1371\/journal.pone.0000990","article-title":"Effect of cellular quiescence on the success of targeted CML therapy","volume":"2","author":"Komarova","year":"2007","journal-title":"PLoS One"},{"key":"2022061706322018300_bib28","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/0008-5472.CAN-08-1959","article-title":"Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies","volume":"69","author":"Komarova","year":"2009","journal-title":"Cancer Res"},{"key":"2022061706322018300_bib29","doi-asserted-by":"crossref","first-page":"e1000447","DOI":"10.1371\/journal.pcbi.1000447","article-title":"Stem cell proliferation and quiescence\u2013two sides of the same coin","volume":"5","author":"Glauche","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"2022061706322018300_bib30","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/bjc.2012.142","article-title":"Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations","volume":"106","author":"Glauche","year":"2012","journal-title":"Br J Cancer"},{"key":"2022061706322018300_bib31","doi-asserted-by":"crossref","first-page":"e0179700","DOI":"10.1371\/journal.pone.0179700","article-title":"Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy","volume":"12","author":"Woywod","year":"2017","journal-title":"PLoS One"},{"key":"2022061706322018300_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","article-title":"Optimal control of treatment in a mathematical model of chronic myelogenous leukemia","volume":"210","author":"Nanda","year":"2007","journal-title":"Math Biosci"},{"key":"2022061706322018300_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cnsns.2015.10.001","article-title":"On the global dynamics of a chronic myelogenous leukemia model","volume":"33","author":"Krishchenko","year":"2016","journal-title":"Commun Nonlinear Sci Numer Simul"},{"key":"2022061706322018300_bib34","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3324\/haematol.2018.201897","article-title":"To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia","volume":"103","author":"Schiffer","year":"2018","journal-title":"Haematologica"},{"key":"2022061706322018300_bib35","doi-asserted-by":"crossref","first-page":"e1000095","DOI":"10.1371\/journal.pcbi.1000095","article-title":"Dynamics and potential impact of the immune response to chronic myelogenous leukemia","volume":"4","author":"Kim","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"2022061706322018300_bib36","first-page":"1875","article-title":"Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses","volume":"277","author":"Wodarz","year":"2010","journal-title":"Proc Biol Sci"},{"key":"2022061706322018300_bib37","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1158\/0008-5472.CAN-15-0611","article-title":"Implication of the autologous immune system in BCR-ABL transcript variations in chronic myelogenous leukemia patients treated with imatinib","volume":"75","author":"Clapp","year":"2015","journal-title":"Cancer Res"},{"key":"2022061706322018300_bib38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11538-017-0272-7","article-title":"Stability analysis of a model of interaction between the immune system and cancer cells in chronic myelogenous leukemia","volume":"80","author":"Besse","year":"2018","journal-title":"Bull Math Biol"},{"key":"2022061706322018300_bib39","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s11538-019-00608-x","article-title":"To cure or not to cure: consequences of immunological interactions in CML treatment","volume":"81","author":"Fassoni","year":"2019","journal-title":"Bull Math Biol"},{"key":"2022061706322018300_bib40","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.2019003395","article-title":"Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML","volume":"135","author":"Gottschalk","year":"2020","journal-title":"Blood"},{"key":"2022061706322018300_bib41","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"2022061706322018300_bib42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ecocom.2016.10.003","article-title":"An ecological resilience perspective on cancer: insights from a toy model","volume":"30","author":"Fassoni","year":"2017","journal-title":"Ecological Complexity"},{"key":"2022061706322018300_bib43","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"key":"2022061706322018300_bib44","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"key":"2022061706322018300_bib45","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"2022061706322018300_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"key":"2022061706322018300_bib47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","article-title":"Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"2022061706322018300_bib48","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.18632\/oncotarget.22279","article-title":"Immune control in chronic myeloid leukemia","volume":"8","author":"Ilander","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706322018300_bib49","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Br\u00fcck","year":"2018","journal-title":"Leukemia"},{"key":"2022061706322018300_bib50","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.7150\/jca.24577","article-title":"Current status and future directions of cancer immunotherapy","volume":"9","author":"Zhang","year":"2018","journal-title":"J Cancer"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/11\/2394\/2791899\/2394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/11\/2394\/2791899\/2394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T19:24:23Z","timestamp":1655493863000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/11\/2394\/641074\/Model-Based-Inference-and-Classification-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,6,2]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-19-2175","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}